So far, our experiments have established that β-catenin in DCs plays a negative role in regulating tumor antigen-specific CD8 T cell responses and that β-catenin-mediated suppression of cross-priming could be reversed by Tim-3 blockade. This evidence concerns the gene HAVCR2 and neoplasm.